Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Eyal Lebel, Vladimir Vainstein, Maayan Ashkenazi, Eran Zimran, Polina Stepensky, Sigal Grisariu & Batia Avni. (2022) Neutrophil decline rate following autologous transplant for lymphoma is a predictor of patients’ outcome. Leukemia & Lymphoma 63:5, pages 1144-1151.
Read now
Read now
Bradley D. Hunter, Michael Rogalski & Caron A. Jacobson. (2019) Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products. Expert Opinion on Biological Therapy 19:11, pages 1157-1164.
Read now
Read now
Giuseppe Milone & Giovanni Tripepi. (2014) Algorithms for early identification of poor mobilization and for on-demand use of plerixafor in patients mobilized by chemotherapy and granulocyte-colony stimulating factor. Leukemia & Lymphoma 55:3, pages 725-726.
Read now
Read now
Articles from other publishers (27)
Luigi Rigacci, Roberta Battistini, Sofia Kovalchuk, Valerio Zoli, Benedetta Puccini, Andrea Evangelista, Luca Arcaini, Leonardo Flenghi, Carlo Visco, Michael Mian, Alice Di Rocco, Claudia Peracchio, Manuel Gotti, Maria Chiara Tisi, Francesca Palombi, Samantha Pozzi, Daniela Gioia, Piera Viero & Maurizio Martelli. (2022) Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study). Hematological Oncology 40:4, pages 609-616.
Crossref
Crossref
Rebecca Cheng, Kayla Scippa, Frederick L. Locke, Julia Thornton Snider & Heather Jim. (2021) Patient Perspectives on Health-Related Quality of Life in Diffuse Large B-Cell Lymphoma Treated with Car T-Cell Therapy: A Qualitative Study. Oncology and Therapy 10:1, pages 123-141.
Crossref
Crossref
Allison M. Bock, Grzegorz S. Nowakowski & Yucai Wang. (2022) Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment. Current Treatment Options in Oncology 23:2, pages 155-170.
Crossref
Crossref
Bei Hu, Danielle Boselli, Lisa M. Pye, Tommy Chen, Rupali Bose, James T. Symanowski, Kris Blackley, Tamara K. Moyo, Ryan Jacobs, Steven I. Park, Amy Soni, Belinda R. Avalos, Edward A. Copelan, Derek Raghavan & Nilanjan Ghosh. (2021) Equal access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B‐cell lymphoma. Cancer 127:21, pages 3991-3997.
Crossref
Crossref
Shuo Wang, Li Wang, Jianda Hu, Wenbin Qian, Xi Zhang, Yu Hu, Qi Zhu, Bobin Chen, Depei Wu, Chung‐Chou H. Chang, Pengpeng Xu, Xiaoyun Zheng, Juying Wei, Yao Liu, Guohui Cui, Yong Tang, Yan Ma, Haiwen Huang, Hongmei Yi & Weili Zhao. (2021) Outcomes in refractory diffuse large B‐cell lymphoma: results from a multicenter real‐world study in China. Cancer Communications 41:3, pages 229-239.
Crossref
Crossref
Norina Tanaka, Yoichi Imai, Kentaro Yoshinaga, Masayuki Shiseki & Junji Tanaka. (2020) Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities. Annals of Hematology 99:11, pages 2577-2586.
Crossref
Crossref
Marie José Kersten, Anne Mea Spanjaart & Catherine Thieblemont. (2020) CD19-directed CAR T-cell therapy in B-cell NHL. Current Opinion in Oncology 32:5, pages 408-417.
Crossref
Crossref
Wei Sang, Ming Shi, Jingjing Yang, Jiang Cao, Linyan Xu, Dongmei Yan, Meixue Yao, Hui Liu, Weidong Li, Bing Zhang, Kemeng Sun, Xuguang Song, Cai Sun, Jun Jiao, Yuanyuan Qin, Tingting Sang, Yuanyuan Ma, Mei Wu, Xiang Gao, Hai Cheng, Zhiling Yan, Depeng Li, Haiying Sun, Feng Zhu, Ying Wang, Lingyu Zeng, Zhenyu Li, Junnian Zheng & Kailin Xu. (2020) Phase II trial of co‐administration of CD19‐ and CD20‐targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma. Cancer Medicine 9:16, pages 5827-5838.
Crossref
Crossref
Caixia Li, Ying Zhang, Changfeng Zhang, Jia Chen, Xiaoyan Lou, Xiaochen Chen, Liqing Kang, Nan Xu, Minghao Li, Jingwen Tan, Xiuli Sun, Jin Zhou, Zhen Yang, Xiangping Zong, Pu Wang, Ting Xu, Changju Qu, Haiwen Huang, Zhengming Jin, Lei Yu & Depei Wu. (2019) Comparison of CAR-T19 and autologous stem cell transplantation for refractory/relapsed non-Hodgkin’s lymphoma. JCI Insight 4:17.
Crossref
Crossref
LaQuisa Hill, Premal Lulla & Helen E Heslop. (2019) CAR‐T cell therapy for non‐Hodgkin lymphomas: A new treatment paradigm. ADVANCES IN CELL AND GENE THERAPY 2:3.
Crossref
Crossref
Yu Cai, Liping Wan, Juan Yang, Jun Zhu, Jieling Jiang, Su Li, Xianmin Song & Chun Wang. (2019) High-dose etoposide could discriminate the benefit from autologous peripheral blood stem cell transplantation in the patients with refractory diffuse large B cell lymphoma. Annals of Hematology 98:4, pages 823-831.
Crossref
Crossref
Genmao Cao, Lijian Lei & Xiaolin Zhu. (2019) Efficiency and safety of autologous chimeric antigen receptor T-cells therapy used for patients with lymphoma. Medicine 98:42, pages e17506.
Crossref
Crossref
Holger Dau, Philipp Kurz & Marc-Denis WeitzeKayane Mheidly, Roch Houot, Michael Scordo & Craig Moskowitz. 2019. Künstliche Photosynthese. Künstliche Photosynthese
157
166
.
Ranjit Nair & Sattva S. Neelapu. (2018) The promise of CAR T-cell therapy in aggressive B-cell lymphoma. Best Practice & Research Clinical Haematology 31:3, pages 293-298.
Crossref
Crossref
Jennifer N. Brudno & James N. Kochenderfer. (2017) Chimeric antigen receptor T-cell therapies for lymphoma. Nature Reviews Clinical Oncology 15:1, pages 31-46.
Crossref
Crossref
Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman, Patrick J. Stiff, Jonathan W. Friedberg, Ian W. Flinn, Andre Goy, Brian T. Hill, Mitchell R. Smith, Abhinav Deol, Umar Farooq, Peter McSweeney, Javier Munoz, Irit Avivi, Januario E. Castro, Jason R. Westin, Julio C. Chavez, Armin Ghobadi, Krishna V. Komanduri, Ronald Levy, Eric D. Jacobsen, Thomas E. Witzig, Patrick Reagan, Adrian Bot, John Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, David Chang, Jeff Wiezorek & William Y. Go. (2017) Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. New England Journal of Medicine 377:26, pages 2531-2544.
Crossref
Crossref
Michael CrumpSattva S. NeelapuUmar FarooqEric Van Den NesteJohn KuruvillaJason WestinBrian K. LinkAnnette HayJames R. Cerhan, Liting ZhuSami BoussettaLei FengMatthew J. Maurer, Lynn Navale, Jeff Wiezorek, William Y. Go & Christian Gisselbrecht. (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130:16, pages 1800-1808.
Crossref
Crossref
Bradley D. Hunter, Megan Herr, Philip J. Meacham, Ferdous Barlaskar, Andrew G. Evans, W. Richard Burack, Jane L. Liesveld, Michael W. Becker, Laurie A. Milner, Louis S. Constine, Sughosh Dhakal, Paul M. Barr, Jonathan W. Friedberg & Carla Casulo. (2017) Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era. Clinical Lymphoma Myeloma and Leukemia 17:3, pages 145-151.
Crossref
Crossref
Santosha A. Vardhana, Craig S. Sauter, Matthew J. Matasar, Andrew D. Zelenetz, Natasha Galasso, Kaitlin M. Woo, Zhigang Zhang & Craig H. Moskowitz. (2017) Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era. British Journal of Haematology 176:4, pages 591-599.
Crossref
Crossref
Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Tanya Siddiqi, Julio C. Chavez, Chitra M. Hosing, Armin Ghobadi, Lihua E. Budde, Adrian Bot, John M. Rossi, Yizhou Jiang, Allen X. Xue, Meg Elias, Jeff Aycock, Jeff Wiezorek & William Y. Go. (2017) Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Molecular Therapy 25:1, pages 285-295.
Crossref
Crossref
Michael Crump. (2016) Management of Relapsed Diffuse Large B-cell Lymphoma. Hematology/Oncology Clinics of North America 30:6, pages 1195-1213.
Crossref
Crossref
Hyun jin Kim, Darae Lee, Kyung-Nam Koh, Sung Han Kang, Hyery Kim, Ho Joon Im & Jong Jin Seo. (2016) Rare Non-Hodgkin Lymphoma in Childhood; A Single Center Experience. Clinical Pediatric Hematology-Oncology 23:2, pages 116-124.
Crossref
Crossref
Maria-Elisabeth GoebelerStefan KnopAndreas ViardotPeter KuferMax S. ToppHermann EinseleRichard NoppeneyGeorg HessStefan KallertAndreas MackensenKathrin RupertusLothar KanzMartin LibicherDirk NagorsenGerhard ZugmaierMatthias KlingerAndreas WolfBrigitte DorschBeate D. QuednauMargit SchmidtJürgen ScheelePatrick A. BaeuerleEugen LeoRalf C. Bargou. (2016) Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. Journal of Clinical Oncology 34:10, pages 1104-1111.
Crossref
Crossref
Clémentine Sarkozy & Bertrand Coiffier. (2015) Primary refractory diffuse large B cell lymphoma in the rituximab era. Current Opinion in Oncology 27:5, pages 377-383.
Crossref
Crossref
Yi-Bin Chen, Shuli Li, David C. Fisher, Jessica Driscoll, Candice Del Rio, Jeremy Abramson, Philippe Armand, Jeffrey Barnes, Jennifer Brown, Corey Cutler, Areej El-Jawahri, Vincent T. Ho, Ephraim Hochberg, Steven McAfee, Ronald Takvorian, Thomas R. Spitzer, Joseph H. Antin, Robert Soiffer & Eric Jacobsen. (2015) Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma. Biology of Blood and Marrow Transplantation 21:9, pages 1583-1588.
Crossref
Crossref
Jordina Rovira, Alexandra Valera, Lluis Colomo, Xavier Setoain, Sonia Rodríguez, Alejandra Martínez-Trillos, Eva Giné, Ivan Dlouhy, Laura Magnano, Anna Gaya, Daniel Martínez, Antonio Martínez, Elías Campo & Armando López-Guillermo. (2014) Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. Annals of Hematology 94:5, pages 803-812.
Crossref
Crossref
Shane Gangatharan & John Kuruvilla. (2013) Relapsed and refractory aggressive NHL: Time for a change. Transfusion and Apheresis Science 49:1, pages 72-79.
Crossref
Crossref